Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas

被引：16

作者：

Pileri, Stefano A. ^{[1
]}

Tripodo, Claudio ^{[2
,3
]}

Melle, Federica ^{[1
]}

Motta, Giovanna ^{[1
]}

Tabanelli, Valentina ^{[1
]}

Fiori, Stefano ^{[1
]}

Vegliante, Maria Carmela ^{[4
]}

Mazzara, Saveria ^{[1
]}

Ciavarella, Sabino ^{[4
]}

Derenzini, Enrico ^{[5
,6
]}

机构：

[1] IEO IRCCS, European Inst Oncol, Div Haematopathol, Via Ripamonti 435, I-20141 Milan, Italy

[2] Univ Palermo, Tumor Immunol Unit, I-90133 Palermo, Italy

[3] FIRC Inst Mol Oncol, Tumor & Microenvironm Histopathol Unit, IFOM, I-20139 Milan, Italy

[4] IRCCS, Hematol & Cell Therapy Unit, Ist Tumori Giovanni Paolo II, Viale Flacco 65, I-70124 Bari, Italy

[5] IEO IRCCS, European Inst Oncol, Div Haematooncol, Via Ripamonti 435, I-20141 Milan, Italy

[6] Univ Milan, Dept Hlth Sci, Via Rudini 8, I-20146 Milan, Italy

来源：

CELLS | 2021年 / 10卷 / 03期

关键词：

diffuse large B-cell lymphoma; gene expression profiling; next-generation sequencing; classification; diagnosis; prognosis; therapy; GENE-EXPRESSION; CLINICAL IMPACT; CLASSIFICATION; ORIGIN; SURVIVAL; CHOP; SIGNATURES; CHEMOTHERAPY; SUBTYPES; PROFILE;

D O I：

10.3390/cells10030675

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Diffuse large B-cell lymphoma (DLBCL) is the commonest form of lymphoid malignancy, with a prevalence of about 40% worldwide. Its classification encompasses a common form, also termed as "not otherwise specified" (NOS), and a series of variants, which are rare and at least in part related to viral agents. Over the last two decades, DLBCL-NOS, which accounts for more than 80% of the neoplasms included in the DLBCL chapter, has been the object of an increasing number of molecular studies which have led to the identification of prognostic/predictive factors that are increasingly entering daily practice. In this review, the main achievements obtained by gene expression profiling (with respect to both neoplastic cells and the microenvironment) and next-generation sequencing will be discussed and compared. Only the amalgamation of molecular attributes will lead to the achievement of the long-term goal of using tailored therapies and possibly chemotherapy-free protocols capable of curing most (if not all) patients with minimal or no toxic effects.

引用

页码：1 / 15

页数：15